Cargando…

Phase 1 Concentration‐QTc and Cardiac Safety Analysis of the MDM2 Antagonist KRT‐232 in Patients With Advanced Solid Tumors, Multiple Myeloma, or Acute Myeloid Leukemia

Cardiac safety and plasma concentration‐QTc interval analyses were completed using data from 2 phase 1 studies of the selective mouse double minute chromosome 2 antagonist, KRT‐232, in patients with solid tumors or multiple myeloma and acute myeloid leukemia (AML) who received KRT‐232 doses of 15 to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taylor, Adekemi, Lee, Dana, Allard, Martine, Poland, Bill, Greg Slatter, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451834/ https://www.ncbi.nlm.nih.gov/pubmed/33460527 http://dx.doi.org/10.1002/cpdd.903

Ejemplares similares

Pharmacokinetics and Macrophage Inhibitory Cytokine‐1 Pharmacodynamics of the Murine Double Minute 2 Inhibitor, Navtemadlin (KRT‐232) in Fed and Fasted Healthy Subjects
por: Wong, Shekman, et al.
Publicado: (2022)

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma
por: Gluck, W. Larry, et al.
Publicado: (2019)

Potent effect of the MDM2 inhibitor AMG232 on suppression of glioblastoma stem cells
por: Her, Nam-Gu, et al.
Publicado: (2018)

Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia
por: Uy, Geoffrey L., et al.
Publicado: (2020)

AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing
por: Sahin, Ilyas, et al.
Publicado: (2020)

Whole-transcriptome bioinformatics revealed HTRA3, KRT8, KRT17, and RHEX as novel targets in acute myeloid leukaemia
por: El-Masry, Omar S., et al.
Publicado: (2022)

Correction: AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing
por: Sahin, Ilyas, et al.
Publicado: (2020)

Analysis of KRT1, KRT10, KRT19, TP53 and MMP9 expression in pediatric and adult cholesteatoma
por: Palkó, Enikő, et al.
Publicado: (2018)

Discovery of Highly Potent p53-MDM2 Antagonists and Structural Basis for Anti-Acute Myeloid Leukemia Activities
por: Huang, Yijun, et al.
Publicado: (2014)

Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
por: Kang, Dongwoo, et al.
Publicado: (2021)

MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388)
por: Khurana, Arushi, et al.
Publicado: (2019)

Identification of presumed pathogenic KRT3 and KRT12 gene mutations associated with Meesmann corneal dystrophy
por: Chen, Judy L., et al.
Publicado: (2015)

KRT8 and KRT19, associated with EMT, are hypomethylated and overexpressed in lung adenocarcinoma and link to unfavorable prognosis
por: Wang, Wenlong, et al.
Publicado: (2020)

Krt14 and Krt15 differentially regulate regenerative properties and differentiation potential of airway basal cells
por: Ievlev, Vitaly, et al.
Publicado: (2023)

PB2205: A MECHANISTIC ABSORPTION AND PHARMACOKINETIC MODEL OF COVALENT BTK INHIBITOR TL-895: INFLUENCE OF FOOD AND ACID REDUCING AGENTS
por: Macwan, Joyce, et al.
Publicado: (2023)

PB2200: FOOD AND ACID REDUCING AGENT EFFECTS ON PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF THE COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) TL-895 IN HEALTHY SUBJECTS
por: Allard, Martine, et al.
Publicado: (2023)

The role of KRT17 in colorectal cancer
por: Ujiie, Daisuke, et al.
Publicado: (2021)

MDM2 Antagonists Counteract Drug-Induced DNA Damage
por: Vilgelm, Anna E., et al.
Publicado: (2017)

A KRT6A and a Novel KRT16 Gene Mutations in Chinese Patients with Pachyonychia Congenita
por: Gong, Li, et al.
Publicado: (2021)

Health Tract, No. 232: Sordid
Publicado: (1865)

A Sporadic Neonatal Case of Epidermolysis Bullosa Simplex Generalized Intermediate with KRT5 and KRT14 Gene Mutations
por: Wakiguchi, Hiroyuki, et al.
Publicado: (2016)

Epithelial Markers aSMA, Krt14, and Krt19 Unveil Elements of Murine Lacrimal Gland Morphogenesis and Maturation
por: Kuony, Alison, et al.
Publicado: (2017)

Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models
por: Lehmann, Christian, et al.
Publicado: (2016)

Recurrent KRT10 Variant in Ichthyosis with Confetti
por: TAKEICHI, Takuya, et al.
Publicado: (2020)

Analysis of KRT5 and KRT14 gene mutations and mode of inheritance in Iranian patients with clinical suspicion of Epidermolysis bullosa simplex
por: Khani, Pouria, et al.
Publicado: (2020)

Problems with Bazett QTc correction in paediatric screening of prolonged QTc interval
por: Andršová, Irena, et al.
Publicado: (2020)

Messe in h-moll, BWV 232
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1984)

Mass in B minor, BWV 232
por: Bach, Johann Sebastian, 1685-1750
Publicado: (1992)

Evaluation of eritoran tetrasodium (E5564), a TLR4 antagonist, on the QTc interval in healthy subjects
por: Nagy, CF, et al.
Publicado: (2011)

The beta-decay scheme of /sup 232/Fr and the K=0 ground-state band in /sup 232/Ra
por: Peräjärvi, K, et al.
Publicado: (2004)

Krt5(+)/Krt15(+) foregut basal progenitors give rise to cyclooxygenase-2-dependent tumours in response to gastric acid stress
por: Moon, Hyeongsun, et al.
Publicado: (2019)

Severe Generalized Epidermolysis Bullosa Simplex in Two Hong Kong Children due to De Novo Variants in KRT14 and KRT5
por: Chong, Shuk Ching, et al.
Publicado: (2020)

Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors
por: Hoffman, Justin, et al.
Publicado: (2019)

Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure–response analysis
por: Fudio, Salvador, et al.
Publicado: (2020)

The corrected QT (QTc) prolongation in hyperthyroidism and the association of thyroid hormone with the QTc interval
por: Lee, Ye Seung, et al.
Publicado: (2015)

Structure of a Stapled Peptide Antagonist Bound to Nutlin-Resistant Mdm2
por: Chee, Sharon Min Qi, et al.
Publicado: (2014)

Small-molecule MDM2 antagonists attenuate the senescence-associated secretory phenotype
por: Wiley, Christopher D., et al.
Publicado: (2018)

Design of indole- and MCR-based macrocycles as p53-MDM2 antagonists
por: Neochoritis, Constantinos G, et al.
Publicado: (2019)

CDK4 inhibition diminishes p53 activation by MDM2 antagonists
por: Sriraman, Anusha, et al.
Publicado: (2018)

Prognostic significance of KRT19 in Lung Squamous Cancer
por: Yuan, Xun, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kep55gf1bupmqibj0joskpirr9